Subtype
Primary Central Nervous System Neoplasm
CI-CAN-00001432Explore in graph →
Non-malignant957 active trials5 approved drugs175 evidence items
- NCIt
- C102871
Loading cancer entity…
Subtype
CI-CAN-00001432Explore in graph →
Clinical trials
3,294 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06193759 | Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)(IMPACT) | recruiting | Phase 1 | 12 | Children's National Research InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07541781 | Sitagliptin in Recurrent/Progressive Grade 4 Glioma | recruiting | Phase 1 | 45 | Kailin Yang, MD, PhDOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04323046 | Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | active not recruiting | Phase 1 | 9 | Sabine Mueller, MD, PhDOTHER | 2 | Jun 15, 2026 | clinicaltrials |
| NCT06104488 | A Study of Avutometinib for People With Solid Tumor Cancers | active not recruiting | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06666712 | Chronic CED of TPT for Recurrent Malignant Glioma(TPT CED rHGG) | recruiting | Phase 1 | 6 | Jeffrey N. BruceOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06914479 | Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors | recruiting | Phase 1 | 11 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07346144 | Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma(ADePT) | recruiting | Phase 1 / Phase 2 | 68 | Trogenix ltdINDUSTRY | 2 | Jun 12, 2026 | clinicaltrials |
| NCT07422363 | Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma | not yet recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 0 | Jun 12, 2026 | clinicaltrials |
| NCT07643870 | Human ADME Study of [14C]-AZD1390 | not yet recruiting | Phase 1 | 8 | AstraZenecaINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04732065 | ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors(PNOC023) | recruiting | Phase 1 | 208 | Sabine Mueller, MD, PhDOTHER | 3 | Jun 11, 2026 | clinicaltrials |
| NCT05283330 | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | recruiting | Phase 1 | 48 | Orano Med Theranostics, SASINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06622434 | New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study(NAVIG-1) | recruiting | Phase 1 / Phase 2 | 35 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05053880 | A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme | active not recruiting | Phase 1 / Phase 2 | 48 | Accendatech USA Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06011109 | Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | recruiting | Phase 1 / Phase 2 | 30 | Aveta Biomics, Inc.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT02649582 | Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients(ADDIT-GLIO) | active not recruiting | Phase 1 / Phase 2 | 20 | University Hospital, AntwerpOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04547777 | Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma | recruiting | Phase 1 | 90 | Darell BignerOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07223034 | A Study of 177Lu-PSMA-617 in People With Gliomas | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04903080 | HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma | active not recruiting | Phase 1 | 50 | Children's Oncology GroupNETWORK | 2 | Jun 2, 2026 | clinicaltrials |
| NCT04978727 | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 35 | Children's Oncology GroupNETWORK | 2 | Jun 2, 2026 | clinicaltrials |
| NCT01269853 | Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | recruiting | Phase 1 / Phase 2 | 54 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02861898 | Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 33 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03213002 | Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM(CAPTEM) | recruiting | Phase 1 / Phase 2 | 67 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06254326 | ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients(ADAGiO) | recruiting | Phase 1 | 12 | University of FloridaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05736406 | A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 12 | Hemerion TherapeuticsINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT07604285 | A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma(NOVA-GBM) | not yet recruiting | Phase 1 / Phase 2 | 36 | Myosin Therapeutics Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT03750513 | LET Optimized IMPT in Treating Pediatric Patients With Ependymoma | recruiting | Phase 1 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07599371 | A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma | recruiting | Phase 1 / Phase 2 | 29 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06724926 | Concurrent Azeliragon With Craniospinal Irradiation | active not recruiting | Phase 1 | 21 | NYU Langone HealthOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04003649 | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | active not recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04477200 | Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma | active not recruiting | Phase 1 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05636618 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | recruiting | Phase 1 / Phase 2 | 300 | Perspective TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors(MRG003) | recruiting | Phase 1 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT02192359 | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06964737 | Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas | recruiting | Phase 1 | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04015700 | Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma | active not recruiting | Phase 1 | 9 | Washington University School of MedicineOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02331498 | Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme(PAZOGLIO) | active not recruiting | Phase 1 / Phase 2 | 51 | Centre Antoine LacassagneOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05293197 | Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients(SONOKID) | recruiting | Phase 1 | 24 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07343986 | Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma(BATs FUS) | recruiting | Phase 1 | 12 | University of VirginiaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07567469 | A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma | not yet recruiting | Phase 1 / Phase 2 | 120 | Regeneron PharmaceuticalsINDUSTRY | 0 | May 5, 2026 | clinicaltrials |
| NCT03491683 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | active not recruiting | Phase 1 / Phase 2 | 52 | Inovio PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT05241392 | Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma | active not recruiting | Phase 1 | 30 | Beijing Tiantan HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05743595 | Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | active not recruiting | Phase 1 | 27 | Washington University School of MedicineOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06176066 | PH Sensitive MRI Based Resections of Glioblastoma | recruiting | Phase 1 | 18 | University of California, Los AngelesOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07560865 | First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma | recruiting | Phase 1 | 9 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562971 | Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES)(FIDES) | not yet recruiting | Phase 1 / Phase 2 | 20 | UMC UtrechtOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05283109 | ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM(ETAPA I) | active not recruiting | Phase 1 | 24 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04540107 | Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma | recruiting | Phase 1 | 300 | Susan ChangOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04922723 | Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma(PRIDE) | active not recruiting | Phase 1 / Phase 2 | 16 | West Virginia UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 17, 2026source: clinicaltrials